Compass Total Operating Expenses from 2010 to 2026

CMPX Stock  USD 5.42  -0.09  -1.63%   
Compass Therapeutics' exhibits slightly volatile volatility while gaining momentum overall. Forward guidance implies movement down to approximately 55.6 M. Total Operating Expenses is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. View All Fundamentals
 
Total Operating Expenses  
 First Reported
2019-06-30
 Previous Quarter
15.8 M
 Current Value
18 M
 Quarterly Volatility
9.5 M
 
Covid
 
Interest Hikes
Financial statement trends for Compass Therapeutics provide structured context on operating performance and capital structure. Track Tax Provision of 0.0, Net Interest Income of 8.8 M or Interest Income of 8.8 M and ratios such as Price To Sales Ratio of 187, Dividend Yield of 0.0 or PTB Ratio of 4.52 to align performance context with Compass Therapeutics Valuation and Volatility.
  
Build AI portfolio with Compass Stock
Compass Therapeutics Correlation provides competitor comparison context for Compass Therapeutics. The view adds relative comparison context.
Learn how to buy and trade Compass Stock using our step-by-step How to Buy Compass Therapeutics guide.
Analyzing Compass Therapeutics's Total Operating Expenses over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Total Operating Expenses has evolved provides context for assessing Compass Therapeutics's current valuation and future prospects.

Latest Compass Therapeutics' Total Operating Expenses Growth Pattern

Below is the plot of the Total Operating Expenses of Compass Therapeutics over the last few years. It is the total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses. Compass Therapeutics' Total Operating Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Compass Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Operating Expenses10 Years Trend
Slightly volatile
   Total Operating Expenses   
       Timeline  

Compass Total Operating Expenses Regression Statistics

Arithmetic Mean 45,087,625
Geometric Mean 43,346,987
Coefficient Of Variation 31.66
Mean Deviation 10,908,765
Median 38,312,000
Standard Deviation 14,276,346
Sample Variance203.8T
Range54.1M
R-Value 0.58
Mean Square Error143.2T
R-Squared 0.34
Significance 0.01
Slope 1,652,150
Total Sum of Squares3261T

Compass Total Operating Expenses History

202655.6 M
202572.8 M
202457.5 M
202350.4 M
202241.7 M
202181.9 M
202027.8 M

How Much Is Compass Therapeutics Worth?

Compass Therapeutics is a small-cap equity in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care categories. Growth expectations are weighed against macro conditions. Defensive traits reduce macro sensitivity. We evaluate Compass Therapeutics through the lens of long-term portfolio construction and diversification efficiency.

Methodology

Unless otherwise specified, financial data for Compass Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Compass (USA Stocks:CMPX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.

Assumptions

The dataset for Compass Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Compass Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

More Resources for Compass Stock Analysis

Reviewing Compass Therapeutics commonly begins with financial statements and performance trends. Key ratios help frame profitability, efficiency, and growth context for Compass Therapeutics Stock. Below are reports that help frame Compass Therapeutics Stock in context:
Compass Therapeutics Correlation provides competitor comparison context for Compass Therapeutics. The view adds relative comparison context.
Learn how to buy and trade Compass Stock using our step-by-step How to Buy Compass Therapeutics guide.
Analysis related to Compass Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
 Earnings Share
-0.45
 Return On Assets
-0.25
 Return On Equity
-0.41
Understanding Compass Therapeutics includes distinguishing between market value and book value, where book value reflects Compass accounting equity. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Market price responds to sentiment, liquidity, and macro shifts, so gaps can appear. Valuation work aligns these measures into a single context.
The concept of value for Compass Therapeutics differs from its quoted price, since each reflects a different lens. Context can include financial performance, operating efficiency, market trends, and peer comparisons. By contrast, market price reflects the level where buyers and sellers transact.